½ÃÀ庸°í¼­
»óǰÄÚµå
1523296

¾ÆÅäÇÇ ÇǺο° ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2030³â)

Atopic Dermatitis Market Report: Trends, Forecast and Competitive Analysis to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Lucintel | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾ÆÅäÇÇ ÇǺο°ÀÇ µ¿Çâ°ú Àü¸Á

¼¼°è ¾ÆÅäÇÇ ÇǺο° ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö 9.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2030³â±îÁö ¾à 233¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ºü¸¥ ±â¼ú ¹ßÀü°ú ÀÚ±Ý Á¶´Þ Áõ°¡, ±×¸®°í ¿¬±¸°³¹ß¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡ÀÔ´Ï´Ù. ¼¼°è ¾ÆÅäÇÇ ÇǺο° ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ ½ÃÀå¿¡¼­ÀÇ ±âȸ·Î ÀÎÇØ À¯¸ÁÇÕ´Ï´Ù.

ºÎ¹®º° ¾ÆÅäÇÇ ÇǺο°

¾ÆÅäÇÇ ÇǺο° ¼¼°è ½ÃÀå¿¡ ´ëÇØ ¾àÁ¦ À¯Çüº°, Åõ¿© ¹æ¹ýº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù.

¾ÆÅäÇÇ ÇǺο° ½ÃÀå ÀλçÀÌÆ®

LucintelÀÇ ¿¹Ãø¿¡ µû¸£¸é, ¾ÆÅäÇÇ ÇǺο°¿¡ ´ëÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È »ý¹°ÇÐÀû Á¦Á¦°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾ÆÅäÇÇ ÇǺο°ÀÇ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ º´¿ø ¾à±¹ÀÌ ÀÌ ½ÃÀå¿¡¼­ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÏ¹Ì´Â ȯÀÚµéÀÇ Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ°í, ÀÌ Áö¿ª¿¡ ¸¹Àº ÀÚü Á¦Á¶¾÷ü°¡ Á¸ÀçÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀ¸·Î ³²À» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÚÁÖ ¹¯´Â Áú¹®

Q1. ½ÃÀå ±Ô¸ð :

A1. ¼¼°è ¾ÆÅäÇÇ ÇǺο° ½ÃÀåÀº 2030³â±îÁö ¾à 233¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q2. ½ÃÀå ¼ºÀå ¿¹ÃøÀº ´ÙÀ½°ú °°½À´Ï´Ù.

A2. ¾ÆÅäÇÇ ÇǺο° ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 9.4%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q3. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ´ÙÀ½°ú °°½À´Ï´Ù.

A3.ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ºü¸¥ ±â¼ú ¹ßÀü°ú ÀÚ±Ý Á¶´Þ Áõ°¡À̸ç, ¿¬±¸ °³¹ß¿¡ ´ëÇÑ Á¤ºÎ Áö¿øµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Q4. ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

A4. ¾ÆÅäÇÇ ÇǺο° ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ ½ÃÀå¿¡¼­ÀÇ ±âȸ·Î ÀÎÇØ À¯¸ÁÇÕ´Ï´Ù.

Q5. ½ÃÀå ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

A5. ¾ÆÅäÇÇ ÇǺο° ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Q6. ÇâÈÄ °¡Àå Å« ½ÃÀå ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

A6. LucintelÀÇ ¿¹Ãø¿¡ µû¸£¸é, ¾ÆÅäÇÇ ÇǺο° Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â °ÍÀº »ý¹°ÇÐÀû Á¦Á¦ÀÔ´Ï´Ù.

Q7. ½ÃÀå¿¡¼­ ÇâÈÄ 5³â°£ °¡Àå Å« ½ÃÀåÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ªÀº ¾îµðÀԴϱî?

A7. ºÏ¹Ì´Â ȯÀÚµéÀÇ Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ°í, ÀÌ Áö¿ª¿¡ ¸¹Àº ÀÚü Á¦Á¶¾÷ü°¡ Á¸ÀçÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È¿¡µµ °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀÔ´Ï´Ù.

Q8. º¸°í¼­ »ç¿ëÀÚ Á¤Àǰ¡ °¡´ÉÇմϱî?

A8. ³×. LucintelÀº Ãß°¡ ºñ¿ë¾øÀÌ 10%ÀÇ »ç¿ëÀÚ Á¤ÀǸ¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå : ½ÃÀå ¿ªÇÐ

  • ¼­·Ð, ¹è°æ, ºÐ·ù
  • °ø±Þ¸Á
  • ¾÷°è ÃËÁø¿äÀΰú °úÁ¦

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2030³â)

  • °Å½Ã°æÁ¦ µ¿Çâ(2018-2023³â)°ú ¿¹Ãø(2024-2030³â)
  • ¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå µ¿Çâ(2018-2023³â)°ú ¿¹Ãø(2024-2030³â)
  • ¾àÁ¦ Ŭ·¡½ºº° ¾ÆÅäÇÇ ÇǺο° ¼¼°è ½ÃÀå
    • PDE-4 ¾ïÁ¦Á¦
    • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
    • »ý¹°ÇÐÀû Á¦Á¦
    • Ä®½Ã´º¸° ¾ïÁ¦Á¦
    • ±âŸ
  • Åõ¿© ¹æ¹ýº° ¾ÆÅäÇÇ ÇǺο° ¼¼°è ½ÃÀå
    • ±¹¼Ò
    • ÁÖ»ç
    • °æ±¸
  • À¯Åë ä³Îº° ¾ÆÅäÇÇ ÇǺο° ¼¼°è ½ÃÀå
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ¿Â¶óÀÎ ¾à±¹

Á¦4Àå Áö¿ªº° ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2023³â)

  • Áö¿ªº° ¾ÆÅäÇÇ ÇǺο° ¼¼°è ½ÃÀå
  • ºÏ¹ÌÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå
  • À¯·´ÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå
  • ±âŸ Áö¿ªÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå

Á¦5Àå °æÀï ºÐ¼®

  • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
  • ¿î¿µ ÅëÇÕ
  • PorterÀÇ Five Forces ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ¿Í Àü·« ºÐ¼®

  • ¼ºÀå ±âȸ ºÐ¼®
  • ¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ
  • Àü·« ºÐ¼®
    • ½ÅÁ¦Ç° °³¹ß
    • ¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå ´É·Â È®´ë
    • ¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° ½ÃÀå¿¡¼­ÀÇ ÀμöÇÕº´(M&A) ¹× ÇÕÀÛÅõÀÚ(JV)
    • ÀÎÁõ°ú ¶óÀ̼±½Ì

Á¦7Àå ÁÖ¿ä ±â¾÷ °³¿ä

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
LSH 24.09.06

Atopic Dermatitis Trends and Forecast

The future of the global atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Atopic Dermatitis by Segment

The study includes a forecast for the global atopic dermatitis by drug class, mode of administration, distribution channel, and region.

Atopic Dermatitis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • PDE-4 Inhibitor
  • Corticosteroids
  • Biologics
  • Calcineurin Inhibitors
  • Others

Atopic Dermatitis Market by Mode of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Topical
  • Injectable
  • Oral

Atopic Dermatitis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Atopic Dermatitis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Atopic Dermatitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies atopic dermatitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the atopic dermatitis companies profiled in this report include-

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Atopic Dermatitis Market Insights

Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Within this market, hospital pharmacy will remain the largest segment due to notable prevalence of atopic dermatitis.

North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Features of the Global Atopic Dermatitis Market

Market Size Estimates: Atopic dermatitis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Atopic dermatitis market size by drug class, mode of administration, distribution channel, and region in terms of value ($B).

Regional Analysis: Atopic dermatitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, mode of administration, distribution channels, and regions for the atopic dermatitis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the atopic dermatitis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the atopic dermatitis market size?

Answer: The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030.

Q2. What is the growth forecast for atopic dermatitis market?

Answer: The global atopic dermatitis market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the atopic dermatitis market?

Answer: The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

Q4. What are the major segments for atopic dermatitis market?

Answer: The future of the atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key atopic dermatitis market companies?

Answer: Some of the key atopic dermatitis companies are as follows:

  • Bayer
  • AbbVie
  • Incyte
  • Novartis International
  • Arcutis Biotherapeutics
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals

Q6. Which atopic dermatitis market segment will be the largest in future?

Answer: Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Q7. In atopic dermatitis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the atopic dermatitis market by drug class (PDE-4 inhibitor, corticosteroids, biologics, calcineurin inhibitors, and others), mode of administration (topical, injectable, and oral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Atopic Dermatitis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Atopic Dermatitis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Atopic Dermatitis Market by Drug Class
    • 3.3.1: PDE-4 Inhibitor
    • 3.3.2: Corticosteroids
    • 3.3.3: Biologics
    • 3.3.4: Calcineurin Inhibitors
    • 3.3.5: Others
  • 3.4: Global Atopic Dermatitis Market by Mode of Administration
    • 3.4.1: Topical
    • 3.4.2: Injectable
    • 3.4.3: Oral
  • 3.5: Global Atopic Dermatitis Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Atopic Dermatitis Market by Region
  • 4.2: North American Atopic Dermatitis Market
    • 4.2.1: North American Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.2.2: North American Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Atopic Dermatitis Market
    • 4.3.1: European Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.3.2: European Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Atopic Dermatitis Market
    • 4.4.1: APAC Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.4.2: APAC Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Atopic Dermatitis Market
    • 4.5.1: ROW Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
    • 4.5.2: ROW Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Atopic Dermatitis Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Atopic Dermatitis Market by Mode of Administration
    • 6.1.3: Growth Opportunities for the Global Atopic Dermatitis Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Atopic Dermatitis Market by Region
  • 6.2: Emerging Trends in the Global Atopic Dermatitis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Atopic Dermatitis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Atopic Dermatitis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer
  • 7.2: AbbVie
  • 7.3: Incyte
  • 7.4: Novartis International
  • 7.5: Arcutis Biotherapeutics
  • 7.6: Bristol-Myers Squibb
  • 7.7: Regeneron Pharmaceuticals
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦